These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study. Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651 [TBL] [Abstract][Full Text] [Related]
6. Natural History and Disease Progression of Early Cardiac Amyloidosis Evaluated by Echocardiography. Itzhaki Ben Zadok O; Eisen A; Shapira Y; Monakier D; Iakobishvili Z; Schwartzenberg S; Abelow A; Ofek H; Kazum S; Ben-Avraham B; Hamdan A; Bental T; Sagie A; Kornowski R; Vaturi M Am J Cardiol; 2020 Oct; 133():126-133. PubMed ID: 32811652 [TBL] [Abstract][Full Text] [Related]
7. Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype. Singulane C; Sun D; Hu Z; Lee L; Sarswat N; Emami Neyestanak M; Patel AR; Lang RM; Addetia K Curr Probl Cardiol; 2024 Sep; 49(9):102729. PubMed ID: 38945183 [TBL] [Abstract][Full Text] [Related]
8. Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis. Henein MY; Suhr OB; Arvidsson S; Pilebro B; Westermark P; Hörnsten R; Lindqvist P Amyloid; 2018 Mar; 25(1):46-53. PubMed ID: 29369708 [TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. Porcari A; Rossi M; Cappelli F; Canepa M; Musumeci B; Cipriani A; Tini G; Barbati G; Varrà GG; Morelli C; Fumagalli C; Zampieri M; Argirò A; Vianello PF; Sessarego E; Russo D; Sinigiani G; De Michieli L; Di Bella G; Autore C; Perfetto F; Rapezzi C; Sinagra G; Merlo M Eur J Heart Fail; 2022 Jul; 24(7):1227-1236. PubMed ID: 35509181 [TBL] [Abstract][Full Text] [Related]
10. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis. Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783 [TBL] [Abstract][Full Text] [Related]
11. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. Donnellan E; Wazni OM; Hanna M; Elshazly MB; Puri R; Saliba W; Kanj M; Vakamudi S; Patel DR; Baranowski B; Cantillon D; Dresing T; Jaber WA JACC Clin Electrophysiol; 2020 Sep; 6(9):1118-1127. PubMed ID: 32972546 [TBL] [Abstract][Full Text] [Related]
12. Atrial electrofunctional predictors of incident atrial fibrillation in cardiac amyloidosis. Sinigiani G; De Michieli L; Porcari A; Zocchi C; Sorella A; Mazzoni C; Bisaccia G; De Luca A; Di Bella G; Gregori D; Perfetto F; Merlo M; Sinagra G; Iliceto S; Perazzolo Marra M; Corrado D; Ricci F; Cappelli F; Cipriani A Heart Rhythm; 2024 Jun; 21(6):725-732. PubMed ID: 38309449 [TBL] [Abstract][Full Text] [Related]
13. Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis. Annabi MS; Carter-Storch R; Zaroui A; Galat A; Oghina S; Kharoubi M; Bezard M; Derumeaux G; Fanen P; Lemonnier F; Poullot E; Itti E; Gallet R; Teiger E; Pibarot P; Damy T; Clavel MA J Am Heart Assoc; 2024 Jul; 13(13):e034723. PubMed ID: 38904242 [TBL] [Abstract][Full Text] [Related]
14. When and how do patients with cardiac amyloidosis die? Escher F; Senoner M; Doerler J; Zaruba MM; Messner M; Mussner-Seeber C; Ebert M; Ensinger C; Mair A; Kroiss A; Ulmer H; Schneiderbauer-Porod S; Ebner C; Poelzl G Clin Res Cardiol; 2020 Jan; 109(1):78-88. PubMed ID: 31134330 [TBL] [Abstract][Full Text] [Related]
15. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease. Rausch K; Scalia GM; Sato K; Edwards N; Lam AK; Platts DG; Chan J Int J Cardiovasc Imaging; 2021 Jan; 37(1):81-90. PubMed ID: 32728989 [TBL] [Abstract][Full Text] [Related]
16. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469 [TBL] [Abstract][Full Text] [Related]
17. Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis. Ioannou A; Porcari A; Patel RK; Razvi Y; Sinigiani G; Martinez-Naharro A; Venneri L; Moon J; Rauf MU; Lachmann H; Wechelakar A; Hawkins PN; Gillmore JD; Fontana M Circ Cardiovasc Imaging; 2023 Jul; 16(7):523-535. PubMed ID: 37431665 [TBL] [Abstract][Full Text] [Related]
18. Clinical and cardiac structural predictors of atrial fibrillation persistence. Bhat A; Chen HHL; Khanna S; Gan GCH; Abhayaratna WP; Nunes MCP; MacIntyre CR; Tan TC Eur J Clin Invest; 2021 Mar; 51(3):e13395. PubMed ID: 32886806 [TBL] [Abstract][Full Text] [Related]
19. Amyloid cardiomyopathy in a large integrated health care system. Czobor P; Hung YY; Baer D; McGlothlin D; Weisshaar D; Zaroff J Am Heart J; 2019 Oct; 216():42-52. PubMed ID: 31401442 [TBL] [Abstract][Full Text] [Related]
20. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]